OnKure Therapeutics, Inc. (OKUR) company profile
Close on Nov 17, 2026Market cap $104.48MP/E –Yield –
About OnKure Therapeutics
Pharmaceutical Preparations, SIC 2834
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases driven by biologically validated mutations. The company uses a structure-based drug design platform combining medicinal chemistry, x-ray crystallography, and computational chemistry to create small molecule therapies that target mutated proteins while sparing wild-type enzymes. Its lead product candidate is OKI-219, an oral selective inhibitor of PI3Kα H1047R being evaluated in Phase 1 clinical trials for advanced breast cancer and other solid tumors. OnKure also pursues discovery programs targeting other PI3Kα mutations and vascular malformations, designing its therapies for patients with genetically defined oncogenic alterations.
The company retains worldwide rights to all its development programs and conducts its clinical trials across international trial sites located in the United States, the European Union, and Asia. OnKure evaluates its therapies across global patient populations while planning future regulatory submissions and commercialization initiatives both domestically and internationally. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of OnKure Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- OnKure Therapeutics, Inc.
- Headquarters
- Boulder, CO
- Address
- 6707 Winchester Circle, Suite 400 80301
- Phone
- (720) 307-2892
- Website
- onkuretherapeutics.com
- Employees
- 45, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Denver, CO
Stock & identifiers
- Ticker
- OKUR
- Former tickers
- RPHM until Oct 8, 2024
- Exchange
- Nasdaq
- IPO date
- Apr 9, 2021
- Shares outstanding
- 40M, Aug 3, 2026
- Public float
- $28.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Oct 7, 2024
- SEC CIK
- 1637715
- CUSIP
- 68277Q105
- ISIN
- US68277Q1058
- FIGI
- BBG00JVRSRC1
- Share class FIGI
- BBG00JVRSRD0
- EIN
- 47-2309515
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nicholas A. Saccomano | President and CEO, Director | 11,160 |
| Jason A. Leverone | Chief Financial Officer | 18,500 |
| Dylan Hartley | Chief Scientific Officer | – |
| Samuel Agresta | Chief Medical Officer | – |
| Isaac Manke | Director | 20,583 |
| Andrew John Phillips | Director | – |
| Michael G. Grey | Director | 494,762 |
| R. Michael Carruthers | Director | 874 |
| Liam Ratcliffe | Director | – |
| Valerie Malyvanh Jansen | Director | – |
| Edward T. Mathers | Director | 15,310 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Nicholas A. Saccomano President and Chief Executive Officer | $600.00K | $609.93K | $247.50K | $10.50K | $1.47M | -85% |
| Samuel Agresta Chief Medical Officer | $482.00K | $211.13K | $144.60K | $14.00K | $851.73K | -70% |
| Jason Leverone Chief Financial Officer | $444.00K | $304.97K | $133.20K | $14.00K | $896.17K | -67% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 9, 2021
- Offer price
- $15.00
- Securities offered
- 6,250,000
- Gross proceeds
- $93.75M
- Exchange
- Nasdaq
- First trading day
- Apr 8, 2021
- First-day close
- $15.000.0%
- Lock-up ends (est.)
- Oct 5, 2021
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 11, 2026, we had 45 employees, 34 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 7, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 8, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 2, 2024 | Name change | Name changed from Reneo Pharmaceuticals, Inc. to OnKure Therapeutics, Inc. |
| Jun 21, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 9, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 6, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?